

04-29-04

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**+** 

			Application Number	10/686,322				
	<b>TRAME :</b>		Filing Date	October 14, 2003				
	TRANSMITTAL	-	First Named Inventor	CHU, GILBERT				
	FORM		Group Art Unit	1634				
	(to be used for all correspondence after in	itial filing)	Examiner Name					
	Total Number of Pages in This Submissi	ion 4 + REFS.	Attorney Docket Number	STAN-277				
		ENCLOSUR	ES (check all that apply)					
	Fee Transmittal Form		nment Papers	After Allowance Communication				
	Fee Attached	Drawin	Application) ng(s)	to Group  Appeal Communication to Board of Appeals and Interferences				
	Amendment / Reply  After Final	Licens	ing-related Papers	Appeal Communication to Group				
	Affidavits/declaration(s)	Petition	n	(Appeal Notice, Brief, Reply Brief)				
	Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Documents		n to Convert to a	Proprietary Information				
			onal Application of Attorney, Revocation	Status Letter				
$\boxtimes$				Other Enclosure(s) (please identify below):				
			nal Disclaimer	1. Form PTO/SB/08A 2. Copies of cited references 3. Postcard				
	Incomplete Application	CD, No	umber of CD(s					
	Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	·					
1	SIGNA	TURE OF APPL	ICANT, ATTORNEY, OR	AGENT				
Signing Attorney/Agent (Reg. No.)  Signature  PAMELA J. SHERWOOD. 36.677 BOZICEVIC. FIELD & FRANCIS LLP								
Date	April 27, 2004							
	EXPRESS MAIL LABEL NO. EV333997627							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## Express Mail No. EV333997627

## INFORMATION DISCLOSURE STATEMENT

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	STAN-277
First Named Inventor	CHU, GILBERT
Application Number	10/686,322
Confirmation No.	7388
Filing Date	October 14, 2003
Group Art Unit	1634
Examiner Name	

Title:

"METHODS AND COMPOSITIONS FOR DETERMINING RISK OF TREATMENT

TOXICITY"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. STAN-277 may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

April 27 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

By:

Pamela J. Sherwood

Registration No. 36,677

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute (CARRENT AND AND TO **Application Number** 10/686,322 **INFORMATION DISCLOSURE** Filing Date October 14, 2003 STATEMENT BY APPLICANT First Named Inventor CHU, GILBERT **Art Unit** 1634 **Examiner Name** (use as many sheets as necessary) **Sheet** 2 **Attorney Docket Number** 1 **STAN-277** 

U.S. PATENT DOCUMENTS								
Examiner Cite Initials' No.1		Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		US-						

		FOREIG	N PATENT DO	UMENTS			
Examiner Initials'	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
		WO 01/84139	11-08-2001	TUSHER et al.			
		OTHER RRIOR ART NO	ON DATENT LI	EDATURE DOCUMENT	-e		
Examiner Initials*	and a series of the series of						
		Barber et al., RELATINSHIP BETWEEN IN VITRO CHROMOSOMAL READIOSENSITIVITY OF PERIPHERAL BLOOD LYMPHOCYTES AND THE EXPRESSION OF NORMAL TISSUE DAMAGE FOLLOWING RADIOTHERAPY FOR BREAST CANCER, (2000), Radiother Oncol, 55:179-86					
		Brock et al., IN VITRO RADIOSENSITIVITY AND NORMAL TISSUE DAMAGE, (2000), Radiother Oncol, 55:93-94					
, and the second		Crompton et al., ALTERED APOPTOTIC PROFILES IN IRRADIATED PATIENTS WITH INCREASED TOXICITY, (1999), Int J Radiat Oncol Biol Phys, 45:707-714					
,		Johansen et al., RELATIONSHIP BETWEEN THE IN VITRO RADIOSENSITIVITY OF SKIN FIBROBLASTS AND THE EXPRESSION OF SUBCUTANEOUS FIBROSIS, TELANGIECTASIA, AND SKIN ERYTHEMA AFTER RADIOTHERAPY, (1996), Radiother Oncol, 40:101-9					
-		Peacock et al., CELLULAR RADIOSENSITIVITY AND COMPLICATION RISK AFTER CURATIVE RADIOTHERAPY, (2000), Radiother Oncol, 55:173-8					
garan .	Russell et al., LOW PREDICTIVE VALUE OF INTRINSIC FIBROBLAST RADIOSENSITIVITY FOR FIBROSIS DEVELOPMENT FOLLOWING RADIOTHERAPY FOR BREAST CANCER, (1998), Int J Radiat Biol, 73:661-70						

	The second secon		
Examiner		Date	
Signature		Considered	

\*EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known		
					Application Number	10/686,322
· ·	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 14, 2003
					First Named Inventor	CHU, GILBERT
	•				Group Art Unit	1634
	(use as many sheets as necessary)				Examiner Name	
Sheet	·· 2	of		2	Attorney Docket Number	STAN-277

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	<del></del>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T²
		Tibshirani et al., DIAGNOSIS OF MULTIPLE CANCER TYPES BY SHRUNKEN CENTROIDS OF GENE EXPRESSION, (2002) Proc. Natl. Acad. Sci. 99:6567-6572	
		Tusher et al., SIGNIFICANCE ANALYSIS OF MICROARRAYS APPLIED TO THE IONIZING RADIATION RESPONSE, (2001), Proc. Natl. Acad. Sci., 98:5116-5121	
p.m			
	•		
و معمو			
		·	
		•	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.